Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

271.36
+4.671.75%
Post-market: 271.740.3825+0.14%16:31 EDT
Volume:5.35M
Turnover:1.46B
Market Cap:479.60B
PE:76.66
High:274.94
Open:268.40
Low:266.89
Close:266.69
52wk High:274.94
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:1.02
T/O Rate:0.30%
Dividend:6.83
Dividend Rate:2.52%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-80.81
PE(LYR):114.98

Loading ...

Movement Alert|AbbVie Rises 3.06% in Regular Trading, Boosted by FDA Breakthrough Therapy Designations for Cancer Drug

Market Focus
·
4 hours ago

Pharma Stocks Rally With Amgen, Gilead Sciences up 3%

Tiger Newspress
·
Yesterday

Micro-Cap Stock Veraxa Biotech is Down 96% This Year. Can Next-Gen Drug Testing Save It?

Dow Jones
·
Yesterday

Morgan Stanley Adjusts Price Target on AbbVie to $310 From $296

MT Newswires Live
·
Yesterday

AbbVie’s telisotuzumab adizutecan gets two FDA Breakthrough Therapy Designations

TIPRANKS
·
Yesterday

AbbVie Says FDA Grants Breakthrough Therapy Status for ABBV-400 in Metastatic Colorectal Cancer

Reuters
·
Yesterday

Abbvie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations from the U.S. FDA for Crc and Nsclc

THOMSON REUTERS
·
Yesterday

Why Vaxcyte Chose A 1.5% Convertible

Macro World​
·
Yesterday

AbbVie's Epkinly Could Be Preferred Frontline DLBCL Agent, UBS Says

MT Newswires Live
·
Yesterday

AbbVie price target raised to $320 from $280 at Scotiabank

TIPRANKS
·
Oct 06

AbbVie Price Target Raised to $320.00/Share from $280.00 by Scotiabank

Dow Jones
·
Oct 06

Scotiabank Adjusts Price Target on AbbVie to $320 From $280, Maintains Sector Outperform Rating

MT Newswires Live
·
Oct 06

European Shares Gain as Genmab Jumps, Bond Yields Retreat

Reuters
·
Oct 06

LIVE Markets-a Health Boost for the STOXX

Reuters
·
Oct 06

Genmab at 3-Year High After Blood Cancer Drug Combination Study Results

Reuters
·
Oct 06

From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run

Bellwether Stocks Movement
·
Oct 06

AbbVie sees Q3 EPS $3.73-$3.77, consensus $3.84

TIPRANKS
·
Oct 06

AbbVie sees FY26 EPS $13.76-$13.96, consensus $14.01

TIPRANKS
·
Oct 06

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

AbbVie Cuts Q3 Adjusted Diluted EPS Outlook to $3.73-$3.77 After $216 Million Acquired Ipr&d, Milestones Expense

Reuters
·
Oct 06